Stemline Therapeutics, Inc.
1675 York Avenue
Suite 30-E
New York
New York
10128
United States
Tel: 212-831-1111
Website: http://www.stemline.com/
Email: info@stemline.com
139 articles about Stemline Therapeutics, Inc.
-
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
1/4/2024
The Menarini Group and Stemline Therapeutics, Inc. announced that they have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.
-
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU®
12/11/2023
The Menarini Group and Stemline Therapeutics, Inc. presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments.
-
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023
12/8/2023
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023.
-
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition
11/20/2023
The Menarini Group and Stemline Therapeutics, Inc. announced that they will present new data related to ORSERDU® and ELZONRIS® in two upcoming congresses.
-
European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
9/20/2023
The Menarini Group and Stemline Therapeutics Inc. announced that the European Commission has approved ORSERDU® as a monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor ‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
-
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2
7/21/2023
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU ® (Elacestrant) for the Treatment of Patients with ER+, HER2.
-
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
5/25/2023
The Menarini Group and Stemline Therapeutics announced results from a new analysis of the pivotal EMERALD clinical study that suggest that oral single-agent elacestrant may be effective in ER+, HER2- advanced or metastatic breast cancer patients with Non-Detected ESR1-mut whose disease has progressed within six months of treatment with a CDK4/6i.
-
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
1/31/2023
Context Therapeutics Inc. today announced that its clinical trial collaborator, Stemline Therapeutics, Inc., a wholly owned subsidiary of The Menarini Group (“Menarini”), received approval from the U.S. Food and Drug Administration (FDA) for ORSERDU.
-
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
1/30/2023
Stemline Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
-
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
1/30/2023
Stemline Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
-
Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.
-
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
8/11/2022
The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of Menarini Group, announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for elacestrant, an investigational selective estrogen receptor degrader, for patients with ER+/HER2- advanced or metastatic breast cancer.
-
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
8/11/2022
The Menarini Group and Stemline Therapeutics announced that the U.S. Food and Drug Administration has accepted the Company’s New Drug Application for elacestrant, an investigational selective estrogen receptor degrader, for patients with ER+/HER2- advanced or metastatic breast cancer.
-
Menarini Group Completes Acquisition of Stemline Therapeutics
6/10/2020
Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics
-
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Stemline Therapeutics Inc.
5/4/2020
Rowley Law PLLC is investigating potential securities law violations by Stemline Therapeutics Inc. (NASDAQ: STML) and its board of directors concerning the proposed acquisition of the company by Menarini Group
-
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million
5/4/2020
Menarini will support further development of Stemline’s ELZONRIS® and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies
-
Shares of New York-based Stemline Therapeutics skyrocketed more than 153% in premarket trading after Italy’s Menarini Group announced a $667 million acquisition of the oncology-focused company.
-
Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results
3/13/2020
Stemline Therapeutics, Inc. reported financial results and business highlights for the fourth quarter ended December 31, 2019.
-
Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020
3/11/2020
Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the company will host a conference call and webcast on Monday, March 16, 2020 at 8:00 a.m. ET to report its fourth quarter 2019 financial results and other business highlights.
-
Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference
2/26/2020
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that management will present at the Cowen 40 th Annual Health Care Conference on Monday, March 2, 2020 at 12:00 PM ET at the Boston Marriott Copley Place in Boston, MA. A live webcast of the presentation can be viewed on the company’s website at www.stemline.com .